BET inhibitors in the treatment of hematologic malignancies: current i | OTT
BeT inhibitors in ongoing early-phase clinical trials for hematologic... | Download Table
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma | EMBO Molecular Medicine
Bromodomain Inhibitor Design For Epigenetic Cancer Therapies and Chemical Probes | Pomerantz Laboratory
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer - eBioMedicine
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis
Next-generation epigenetic inhibitors
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology
Cancers | Free Full-Text | Role of BET Inhibitors in Triple Negative Breast Cancers | HTML
Targeting MYC dependence in cancer by inhibiting BET bromodomains | PNAS
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study - The Lancet Haematology
BET bromodomain inhibitor | Epigenetic Reader Domain Inhibitor | MedChemExpress
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors | Journal of Clinical Oncology
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer - ScienceDirect
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression - ScienceDirect
Bromodomain inhibitors in clinical trials | Download Table
Drug Toxicities With BET Inhibitors in Clinical Trials a | Download Table
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy | Future Science OA
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML | Oncogene
Differentiation therapy of myeloid leukemia: four decades of development | Haematologica
Clinical trials evaluating BET inhibitors with results in patients with... | Download Scientific Diagram
Two pathways, one destination: promising drug combination to treat ovarian cancer
Cancers | Free Full-Text | Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications | HTML
Achieving clinical success with BET inhibitors as anti-cancer agents | British Journal of Cancer
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
